p53 is activated in response to disruption of the pre-mRNA splicing machinery
- PMID: 22349816
- DOI: 10.1038/onc.2012.38
p53 is activated in response to disruption of the pre-mRNA splicing machinery
Abstract
In this study, we show that interfering with the splicing machinery results in activation of the tumour-suppressor p53. The spliceosome was targeted by small interfering RNA-mediated knockdown of proteins associated with different small nuclear ribonucleoprotein complexes and by using the small-molecule splicing modulator TG003. These interventions cause: the accumulation of p53, an increase in p53 transcriptional activity and can result in p53-dependent G(1) cell cycle arrest. Mdm2 and MdmX are two key repressors of p53. We show that a decrease in MdmX protein level contributes to p53 activation in response to targeting the spliceosome. Interfering with the spliceosome also causes an increase in the rate of degradation of Mdm2. Alterations in splicing are linked with tumour development. There are frequently global changes in splicing in cancer. Our study suggests that p53 activation could participate in protection against potential tumour-promoting defects in the spliceosome. A number of known p53-activating agents affect the splicing machinery and this could contribute to their ability to upregulate p53. Preclinical studies indicate that tumours can be more sensitive than normal cells to small-molecule spliceosome inhibitors. Activation of p53 could influence the selective anti-tumour activity of this therapeutic approach.
Similar articles
-
A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein.PLoS One. 2017 Oct 3;12(10):e0185801. doi: 10.1371/journal.pone.0185801. eCollection 2017. PLoS One. 2017. PMID: 28973015 Free PMC article.
-
Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.Cell Cycle. 2008 Jun 1;7(11):1604-12. doi: 10.4161/cc.7.11.5929. Epub 2008 Mar 17. Cell Cycle. 2008. PMID: 18520179
-
ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.EMBO J. 2005 Oct 5;24(19):3411-22. doi: 10.1038/sj.emboj.7600812. Epub 2005 Sep 15. EMBO J. 2005. PMID: 16163388 Free PMC article.
-
Regulation of p53: a collaboration between Mdm2 and Mdmx.Oncotarget. 2012 Mar;3(3):228-35. doi: 10.18632/oncotarget.443. Oncotarget. 2012. PMID: 22410433 Free PMC article. Review.
-
Mdmx and Mdm2: brothers in arms?Cell Cycle. 2004 Jul;3(7):900-4. Epub 2004 Jul 2. Cell Cycle. 2004. PMID: 15254433 Review.
Cited by
-
Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity.Oncotarget. 2018 May 1;9(33):23029-23046. doi: 10.18632/oncotarget.25196. eCollection 2018 May 1. Oncotarget. 2018. PMID: 29796170 Free PMC article.
-
Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6181-91. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26261495 Free PMC article.
-
A common cellular response to broad splicing perturbations is characterized by metabolic transcript downregulation driven by the Mdm2-p53 axis.Dis Model Mech. 2024 Feb 1;17(2):dmm050356. doi: 10.1242/dmm.050356. Epub 2024 Mar 1. Dis Model Mech. 2024. PMID: 38426258 Free PMC article.
-
DDX5 plays essential transcriptional and post-transcriptional roles in the maintenance and function of spermatogonia.Nat Commun. 2019 May 23;10(1):2278. doi: 10.1038/s41467-019-09972-7. Nat Commun. 2019. PMID: 31123254 Free PMC article.
-
PRPF8 defects cause missplicing in myeloid malignancies.Leukemia. 2015 Jan;29(1):126-36. doi: 10.1038/leu.2014.144. Epub 2014 Apr 30. Leukemia. 2015. PMID: 24781015 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous